.jpg)
1 hour ago
2
Article content
WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Second Quarter 2026 Financial Highlights:
Article content
Article content
- Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely of sales from legacy animal health operations and the legacy DermaKB® product line, both of which the Company has since exited as part of its strategic transition to a focused human wound care business. Kane Biotech remains focused on accelerating commercialization of the revyve® portfolio in Canada and the United States by building market awareness, expanding distribution, and supporting broader adoption of its antimicrobial wound care products.
- Gross profit for the second quarter of 2026 was $1,444 compared to a gross loss of $(45,526) for the second quarter of 2025. The improvement reflects the Company’s transition from legacy operations to the early commercialization of its revyve portfolio, as initial market development activities and product sales began to support positive gross margin contribution.
- Total operating expenses for the three months ended June 30, 2026 were $785,927 compared to $229,930 for the three months ended June 30, 2025. The increase was primarily attributable to the impact of stock option expense recorded in the current period and one-time reversals of compensation-related accruals recorded in the comparative period. These increases were partially offset by lower other administration costs and lower research and development expenses, including reduced contract research, patent-related and other research costs.
- Net loss for the second quarter of 2026 was $(833,636) compared to a net loss of $(348,541) for the second quarter of 2025. The increase in net loss was due primarily to higher operating expenses recorded in the current period, as described above.
Article content
Article content
Cash at June 30, 2026 was $854,729.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Kane Biotech’s June 30, 2026 Financial Statements and the Management Discussion and Analysis with regards thereto are now available on SEDAR+ and the Company’s website.
Article content
Corporate Update:
Article content
During the second quarter of 2026 and subsequent to quarter-end, Kane Biotech continued to execute on its strategy to commercialize and further develop its revyve antimicrobial wound care portfolio. The Company’s activities during the period focused on expanding market access in Canada and the United States, advancing clinical and scientific validation, strengthening its regulatory and quality infrastructure, securing additional financing, and evaluating strategic opportunities to support long-term growth.
Article content
2026 Objectives and Progress to Date
Article content
Kane entered 2026 with defined commercial, clinical and product-development objectives for its revyve and broader biofilm-focused portfolio. Through the second quarter and subsequent to quarter-end, the Company has made progress across these priorities:
Article content
- Clinical evidence: Clinical evaluations and case series are underway, or pending research approval, at multiple sites in Canada and the United States, and a North American revyve real-world data registry has been initiated.
- Scientific engagement: Preclinical and clinical data have been presented at selected meetings, with additional presentations planned for upcoming wound care conferences.
- Commercial expansion: The Company continues to expand its U.S. and Canadian distributor networks within targeted sales channels and geographic markets to support growth of the revyve product line.
- Scientific Advisory Board: A multidisciplinary Scientific Advisory Board has been established, with its first meeting planned for the fourth quarter of 2026.
- Portfolio development: Ongoing activities include contract manufacturing scale-up and validation for the revyve Antimicrobial Skin and Wound Cleanser, proof-of-concept testing for the coactiv+ Antimicrobial Surgical Gel and smaller-format packaging work for revyve Wound Spray.
- DispersinB Hydrogel: The Company plans to initiate biocompatibility testing in the third quarter of 2026 as it prepares the program for a safety clinical trial targeted to commence in 2027.
Article content
Article content
“During the second quarter and subsequent to quarter-end, Kane continued to advance its transition into a focused human wound care commercialization company,” said Dr. Robert Huizinga, Interim CEO. “We strengthened our commercial foundation through expanded distribution relationships and sales infrastructure, continued to build clinical and scientific support for the revyve platform, completed additional financing, and initiated a strategic review process to evaluate opportunities that may support the Company’s next stage of growth. Our focus remains on expanding access to revyve, supporting adoption among clinicians and customers, and creating long-term value for shareholders.”
Article content
About Kane Biotech Inc. (TSX-V:KNE)
Article content
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
English (US)